IFNG and macrophage activation syndrome: In this cohort of patients, we did not find a mention of other drugs that have been recently used in recent years for the treatment of s-JIA-related MAS, such as anti-IL6 therapies (tocilizumab), anti-IFN-γ monoclonal antibody (emapalumab) and Janus kinase (JAK) inhibitors (ruxolitinib) [80].